Home » Trubion Signs Leukemia Drug Agreement Worth up to $196 Million
Trubion Signs Leukemia Drug Agreement Worth up to $196 Million
Trubion will get $20 million upfront from Redwood City, Calif.-based Facet and may get up to $176 million more for the worldwide development and commercialization of its chronic lymphocytic leukemia drug if certain development, regulatory and sales milestones are met.
Puget Sound Business Journal
Puget Sound Business Journal
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May